Eton Pharmaceuticals, Inc. (ETON) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.45%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.93%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.45% | Research and development expense / revenue. Period ending 2026-06-30. $5.76M ÷ $105.59M × 100 ≈ 5.45% |
| Stock-based compensation / revenue · 12 months | 4.93% | Share-based compensation / revenue. Period ending 2026-06-30. $5.20M ÷ $105.59M × 100 ≈ 4.93% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 5.76M USD | Research and Development Expense |
| Revenue | 105.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 5.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 16.31M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.76M | $105.59M | $5.20M | $16.31M | (m) | 5.45% | 4.93% | (m) | (m) |
| 2026-03-31 | $8.48M | $86.93M | $5.83M | $2.04M | (m) | 9.75% | 6.71% | (m) | (m) |
| 2025-12-31 | $7.76M | $79.95M | $5.51M | $-844.00K | (m) | 9.71% | 6.89% | (m) | (m) |
| 2025-09-30 | $5.11M | $70.32M | $5.17M | $-2.68M | (m) | 7.27% | 7.35% | (m) | (m) |
| 2025-06-30 | $4.51M | $58.18M | $4.80M | $-807.00K | (m) | 7.75% | 8.25% | (m) | (m) |
| 2025-03-31 | $3.77M | $48.33M | $3.54M | $-2.27M | (m) | 7.79% | 7.33% | (m) | (m) |
| 2024-12-31 | $3.25M | $39.01M | $3.17M | $-2.60M | (m) | 8.34% | 8.11% | (m) | (m) |
| 2024-09-30 | $5.17M | $34.68M | $3.13M | $-5.22M | $927.00K | 14.92% | 9.03% | -5.63× | Reported |
| 2024-06-30 | $5.28M | $31.38M | $3.14M | $-6.28M | $982.00K | 16.84% | 10.01% | -6.39× | Reported |
| 2024-03-31 | $3.44M | $34.30M | $3.09M | $542.00K | $1.03M | 10.02% | 9.00% | 0.52× | Reported |
| 2023-12-31 | $3.32M | $31.64M | $3.14M | $-1.19M | $1.06M | 10.50% | 9.91% | -1.12× | Reported |
| 2023-09-30 | $3.22M | $32.83M | $3.27M | $1.86M | $955.00K | 9.81% | 9.97% | 1.95× | Reported |
| 2023-06-30 | $3.35M | $29.02M | $3.49M | $-484.00K | $1.03M | 11.54% | 12.03% | -0.47× | Reported |
| 2023-03-31 | $2.91M | $24.38M | $4.01M | $-5.71M | $973.00K | 11.95% | 16.44% | -5.87× | Reported |
| 2022-12-31 | $4.00M | $21.25M | $4.22M | $-8.26M | $955.00K | 18.80% | 19.85% | -8.65× | Reported |
| 2022-09-30 | $3.73M | $18.85M | $4.20M | $-8.01M | $975.00K | 19.81% | 22.26% | -8.21× | Reported |
| 2022-06-30 | $5.67M | $16.40M | $4.25M | $-10.96M | $995.00K | 34.55% | 25.94% | -11.02× | Reported |
| 2022-03-31 | $6.97M | $12.11M | $3.79M | $-11.95M | $1.02M | 57.53% | 31.30% | -11.65× | Reported |
| 2021-12-31 | $6.24M | $21.83M | $3.38M | $-1.50M | $1.04M | 28.56% | 15.49% | -1.43× | Reported |
| 2021-09-30 | $8.96M | $15.82M | $3.29M | $-10.23M | $1.03M | 56.61% | 20.80% | -9.90× | Reported |
| 2021-06-30 | $9.10M | $14.88M | $3.01M | $-10.65M | $1.01M | 61.16% | 20.20% | -10.54× | Reported |
| 2021-03-31 | $8.72M | $11.84M | $2.88M | $-12.87M | $953.00K | 73.68% | 24.36% | -13.50× | Reported |
| 2020-12-31 | $14.10M | $39.00K | $2.58M | $-27.11M | $884.00K | 36164.10% | 6605.13% | -30.67× | Reported |
| 2020-09-30 | $10.94M | $417.00K | $2.30M | $-22.35M | (m) | 2622.54% | 552.52% | (m) | (m) |
| 2020-06-30 | $11.53M | $578.00K | $2.12M | $-21.12M | (m) | 1994.46% | 366.26% | (m) | (m) |
| 2020-05-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $11.36M | $558.00K | $1.91M | $-19.93M | (m) | 2035.48% | 341.94% | (m) | (m) |
| 2019-12-31 | $11.55M | $959.00K | $1.89M | $-18.60M | (m) | 1204.90% | 196.87% | (m) | (m) |
| 2019-09-30 | $12.42M | (m) | $1.61M | $-18.23M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $10.55M | (m) | $1.23M | $-15.56M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $10.82M | (m) | $1.15M | $-14.91M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $5.63M | (m) | $1.85M | $-10.32M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |